XFLH Capital signs non-binding LOI to combine with Renogen Biolab

XFLH Capital Corp

On Sept 18, 2026, XFLH Capital entered a non-binding letter of intent for a business combination with Renogen Biolab Inc., a Canadian health service provider.
Renogen Biolab offers DNA services, vector engineering, and protein expression; parties will negotiate definitive agreements with due diligence access.
No deal value, premium, or closing conditions disclosed; the LOI is non-binding and subject to negotiation of Definitive Agreements.
XFLH is a Cayman Islands blank-check SPAC; its units, ordinary shares, and rights trade on NYSE under XFLHU, XFLH, XFLHR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.